R&D channel feed – Endpoints News

R&D channel feed

Warring with ex-CEO, options shrinking, Aeterna Zentaris turns to a strategic review

8 years ago

Sanofi believes it’s still not too late to become a top player in cancer drug market

8 years ago

Esperion shares bounce up on an effective triplet approach to slashing LDL

8 years ago

Prepping for a rapid-fire launch, Kite Pharma gets a pass from FDA on axi-cel panel review

8 years ago

FibroGen shares rocket up on positive PhII data in idiopathic pulmonary fibrosis

8 years ago

Zynerba goes into meltdown mode as cannabis-derived drug flops in PhII

8 years ago

A small, groundbreaking cardio study pushes MyoKardia to a pivotal showdown — shares soar

8 years ago

GSK déjà vu: Time for a top-down switch as new CEO tries to conquer old R&D demons

8 years ago

Gemphire shares crater after its LDL drug comes up short in PhIIb

8 years ago

Eli Lilly’s new, $1B pain drug racks up another promising round of PhIII pain data

8 years ago

Dynavax shares dip after FDA asks for more time to sort out Heplisav post-marketing plan

8 years ago

Bristol-Myers beefs up big cancer drug pipeline, buying IFM drugs in $2.3B-plus deal

8 years ago

10 years and $100M-plus later, GSK shutters a China R&D site during a major pipeline overhaul

8 years ago

Shire plots an ADHD public spinoff as CEO Ornskov completes a top-to-bottom overhaul

8 years ago

After a $200M financing, Highland Therapeutics falls silent on ADHD drug’s fate as PDUFA sails by

8 years ago

Spark Therapeutics offers a glimpse of efficacy in first two hemophilia A gene therapy patients

8 years ago

Following PhIII breakdown, AstraZeneca cruises toward an FDA decision for its BTK blockbuster hopeful acalabrutinib

8 years ago

InVivo Therapeutics shares tank after a third patient death in lead study

8 years ago

Dynavax takes a big step toward an OK for hep B vaccine, but nagging safety issues remain

8 years ago

Merck admits cyberattack is having an impact on research, manufacturing — we're just not sure how big

8 years ago

The global rivalry for top scientific talent in biopharma R&D is about to get a lot hotter

8 years ago

CheckMate-227: Bristol-Myers Squibb has a MYSTIC-sized problem on its hands

8 years ago

J&J sews up an expanded vaccine pact with Bavarian Nordic, paying $43M for HIV, hep B projects

8 years ago

Alexion joins the R&D reorganization gala, pruning a slate of projects and revving up new deals

8 years ago

First page Previous page 291 292 293294295 296 297 Next page Last page